Arzerra (Ofatumumab) for Treatment of Chronic Lymphocytic Leukaemia (CLL)
Arzerra (ofatumumab) is the first-line drug approved for the treatment of chronic lymphocytic leukaemia (CLL). The drug is developed and ...
Arzerra (ofatumumab) is the first-line drug approved for the treatment of chronic lymphocytic leukaemia (CLL). The drug is developed and ...
Achillion Pharmaceuticals, Inc., which was founded in February 2000 as one of the largest biotech start-ups in the USA, occupies ...
Australia-based regenerative medicine company Mesoblast has signed an agreement with the US National Institutes of Health's (NIH) National Heart, Lung ...
Bristol-Myers Squibb and Allied Minds have formed a new jointly owned enterprise, Allied-Bristol Life Sciences, aimed at advancing discoveries of ...
The US Food and Drug Administration (FDA) has approved Jardiance (empagliflozin) tablets, developed by Boehringer Ingelheim Pharmaceuticals and Eli Lilly ...
The courier firm FedEx faces drug-trafficking charges after being indicted by a federal grand jury in California, in a case ...
The US Food and Drug Administration (FDA) has expressed concerns over the manufacturing process of at least one product at ...
Bayer has announced the US Food and Drug Administration's (FDA) approval of Eylea, an aflibercept solution for injection into the ...
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that BELVIQ(R) (lorcaserin HCl) has been nominated by the Galien ...
STALLERGENES (Paris:GENP), a global healthcare company specialized in the diagnosis and treatment of allergies through allergen immunotherapy-based solutions, announced today ...
Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.
